{"id":"NCT00235391","sponsor":"Novartis Pharmaceuticals","briefTitle":"Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload","officialTitle":"A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2005-10-10","resultsPosted":"2011-05-02","lastUpdate":"2011-06-07"},"enrollment":1683,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Thalassemia","Sickle Cell Disease","Diamond Blackfan Anemia","Myelofibrosis"],"interventions":[{"type":"DRUG","name":"Deferasirox","otherNames":[]}],"arms":[{"label":"Deferasirox","type":"EXPERIMENTAL"}],"summary":"This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.","primaryOutcome":{"measure":"Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events","timeFrame":"Baseline to end of study (Median exposure time to drug was approximately 30 weeks; Maximum exposure was 104 weeks)","effectByArm":[{"arm":"2 to < 6 Years","deltaMin":0,"sd":null},{"arm":"6 to < 12 Years","deltaMin":0,"sd":null},{"arm":"12 to < 16 Years","deltaMin":1,"sd":null},{"arm":"16 to < 50 Years","deltaMin":4,"sd":null},{"arm":"50 to < 65 Years","deltaMin":0,"sd":null},{"arm":"≥ 65 Years","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":141,"countries":["United States","Belgium","Canada","Germany","Greece","Italy","Netherlands","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.novartisclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":194,"n":1683},"commonTop":["Rash"]}}